- Media
- Press Releases
April 24 2025
Indivior Announces Q1 2025 Financial Results
February 27 2025
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
February 24 2025
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
February 20 2025
Indivior Announces FY and Q4 2024 Financial Results
November 7 2024
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
October 24 2024
Indivior Announces Q3 2024 Financial Results
October 10 2024
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
October 7 2024
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
September 4 2024
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
August 26 2024
Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness
July 25 2024
Indivior Announces Q2 2024 Financial Results
May 23 2024
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
April 25 2024
Indivior Announces Q1 2024 Financial Results
February 22 2024
Indivior Announces Q4 / FY 2023 Financial Results
December 20 2023
Indivior Settles Patent Dispute with Teva Subsidiary Actavis
November 9 2023
Indivior Announces Q3 2023 Financial Results
October 23 2023
Indivior Reaches Agreement with Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results
August 21 2023
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
July 27 2023
Indivior Announces H1 and Q2 2023 Financial Results
June 12 2023
Indivior to Commence Trading on Nasdaq
April 27 2023
Indivior Announces Q1 2023 Financial Results
February 16 2023
Indivior Announces FY 2022 Financial Results
December 7 2022
Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
November 14 2022
Indivior to Acquire Opiant Pharmaceuticals
October 27 2022
Indivior Announces Q3 2022 Financial Results
September 6 2022
Indivior To Participate in Upcoming Investor Healthcare Events
September 1 2022
Indivior Recognizes National Recovery Month, Commits to Helping Move People living with Opioid Use Disorder onto a Path to Hope and Recovery
July 28 2022
Indivior Announces H1 and Q2 2022 Financial Results
April 28 2022
Indivior Announces Q1 2022 Financial Results
April 27 2022
The Board of Indivior PLC today announces the appointment of Barbara Ryan as an Independent Non-Executive Director
February 16 2022
Indivior Announces Q4 / FY 2021 Financial Results
October 21 2021
Indivior to Present New Data on Opioid Use Disorder at CSAM-SMCA 2021 Scientific Conference
September 14 2021
Indivior to Participate in Upcoming Healthcare Events During National Recovery Month
September 9 2021
Indivior to Participate in Upcoming Investor Conferences
July 27 2021
Indivior Announces H1 and Q2 2021 Financial Results
June 30 2021
Indivior Raises FY 2021 Guidance
June 24 2021
Indivior Presents New Data at the College on Problems of Drug Dependence (CPDD) 2021 Annual Conference
April 29 2021
Indivior Announces Q1 2021 Financial Results
April 22 2021
Indivior Welcomes White House Announcement Prioritizing Expanded Access to Evidence-Based Treatment
April 22 2021
Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic
March 24 2021
Board Appointments and Succession Plan Announced
March 22 2021
Indivior Recognizes Drug and Alcohol Facts Week® 2021
February 18 2021
Indivior Announces FY 2020 Financial Results
February 18 2021
Indivior FY 2020 Financial Results Presentation
January 25 2021
Indivior Reaches Settlement with Reckitt Benckiser
November 27 2020
Claim filed by Reckitt Benckiser Group plc
November 20 2020
Appointment of Chief Financial Officer
November 19 2020
Appointment of Non-Executive Chair
November 13 2020
US Court Approval of Agreement with Justice Department
October 29 2020
Indivior Announces 2020 Nine Months Financial Results
October 23 2020
US Court Sentencing of Former CEO
September 30 2020
Indivior Calls for Widespread Commitment to Tackling Stigma in Patients with Opioid Use Disorder
September 24 2020
Indivior Takes Strategic Alignment Actions
September 22 2020
Indivior Underscores Commitment to Putting Patients First during this Recovery Month
September 8 2020
Indivior PLC - Board Announcement
September 4 2020
Motion to Expedite DRL’s Appeal of Indivior’s Preliminary Injunction Granted-in-Part
July 24 2020
An Open Letter to our Stakeholders from our Interim Board Chair and CEO regarding Indivior Agreement
July 24 2020
Indivior Announces Agreement to Resolve Criminal Charges and Civil Complaints Related to SUBOXONE® Film
June 30 2020
US Government Agreement with Former CEO
June 29 2020
Appointment of Chief Executive Officer
May 14 2020
Q1 2020 Indivior Financial Results Press Release
April 27 2020
Directorate Change
April 20 2020
Indivior to Announce Q1 2020 Results - May 14th
March 23 2020
One-Year Outcomes of Real-World RECOVER™ Study Published in Journal of Addiction Medicine
February 13 2020
Indivior Announces FY 2019 Financial Results
February 10 2020
Indivior to Announce and Present FY 2019 Results on February 13th
December 10 2019
Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder
December 2 2019
New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes
October 15 2019
Indivior Raises FY 2019 Net Revenue and Net Income Guidance
September 26 2019
Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative
July 31 2019
Indivior Directorate Changes
July 31 2019
Indivior Announces H1 2019 Financial Results
July 29 2019
Indivior PLC – Director’s Change of Responsibilities
July 15 2019
Indivior Announces Ruling by the Court of Appeals for the Federal Circuit in ANDA Litigation
July 11 2019
Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m
May 2 2019
Indivior PLC Q1 2019 Financial Results
April 9 2019
Company Believes U.S. Justice Department Is Fundamentally Wrong, Will Contest Charges Vigorously
February 27 2019
Indivior Announces Launch of PERSERIS™ (risperidone) for the Treatment of Schizophrenia in Adults
February 20 2019
Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic
February 14 2019
Indivior PLC FY 2018 Financial Results
February 12 2019
Court of Appeals for the Federal Circuit Denies Motion to Stay Issuance of the Mandate
February 4 2019
Indivior to Divest Interest in China
February 4 2019
Indivior Enters into Agreement with Alvogen on Generic (buprenorphine and naloxone) Sublingual Film
January 25 2019
Indivior Is Granted Temporary Restraining Order on Generic (buprenorphine and naloxone) Sublingual Film
January 21 2019
Indivior to Announce FY 2018 Results on February 14th
December 18 2018
Trading Update Release
December 12 2018
Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling
November 30 2018
Indivior Prepays Debt
November 21 2018
Court of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film
November 20 2018
Indivior Statement on Court Decision
November 6 2018
Indivior Announces Upcoming Investor Events
November 1 2018
Indivior Q3 2018 Financial Results
October 24 2018
SUPPORT for Patients and Communities Act of 2018
October 19 2018
Third Quarter Results Notification & Call Information
September 26 2018
Indivior Provides Update on Key Business Drivers and Expectations
September 12 2018
Indivior unable to attend Investor Conference
September 10 2018
Indivior Prepays $150 Million of Outstanding Debt
September 4 2018
Morgan Stanley Annual Global Healthcare Conference
August 21 2018
Holding(s) in Company 08/21/2018
August 10 2018
Holding(s) in Company 8/10/2018
August 6 2018
Holding(s) in Company 8/6/2018
July 31 2018
Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld
July 25 2018
Indivior H1 2018 Financial Results
June 15 2018
Indivior Is Granted Temporary Restraining Order
May 17 2018
Result of AGM
May 1 2018
Indivior Q1 2018 Results On Track. FY 2018 Guidance Reconfirmed. Encouraging SUBLOCADE™ Launch.
April 20 2018
March 29 2018
Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery’s Orexin-1 (OX1) Antagonist Program
March 23 2018
Indivior Responds To Court Ruling In ANDA Litigation And Announces Intention To Appeal
February 15 2018
Indivior PLC Full Year 2017 Financial Results
February 6 2018
Indivior to Announce Full Year 2017 Results on February 15th
February 1 2018
January 11 2018
JP Morgan Healthcare Conference Presentation – Strengthening Our Global Leadership in Treatment of Addiction
January 3 2018
Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABAB PAMs for Addiction Disorder Treatments
December 19 2017
Indivior Announces Repricing and Maturity Extension of Term Loan Facilities and Replacement of Credit Facility
November 2 2017
Q3 / YTD 2017 Financial Results
October 31 2017
FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder
October 3 2017
FDA Posts Advisory Committee Meeting Notice for RBP-6000 NDA
October 2 2017
Indivior Submits New Drug Application to U.S. FDA for RBP-7000 Risperidone Monthly Depot for Treatment of Schizophrenia
September 27 2017
Indivior Chief Medical Officer Ponni Subbiah, M.D., Provides Testimony Before the Presidential Commission on Combating Drug Addiction and the Opioid Crisis
September 25 2017
Indivior Enters into Settlement with Mylan Pharmaceuticals in Patent Infringement Case
September 2 2017
Indivior Asserts New Patent Against ANDA Filers
September 1 2017
Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal
August 22 2017
Indivior Opens $30 Million Research and Development Center to Advance Treatment Innovation
July 31 2017
Indivior’s NALSCUE® Receives Marketing Authorization from French Regulatory Agency ANSM
July 27 2017
Indivior H1 2017 Financial Results
June 29 2017
Reminder RBP-6000 Investor Event Announcement
June 21 2017
RBP-6000 Data Presented in Late-Breaking Research Oral Session at CPDD 79th Annual Scientific Meeting
June 16 2017
RBP-6000 Investor Event Announcement
May 30 2017
Indivior Submits New Drug Application to U.S. FDA for RBP-6000 Buprenorphine Monthly Depot
May 23 2017
Indivior’s Shaun Thaxter to present at the Jefferies Global Healthcare Conference on June 6th
May 17 2017
2017 Annual General Meeting
March 28 2017
RBP-6000 Phase 3 PK/PD/RO and HEOR Subanalyses
March 13 2017
Indivior RBP-7000 Top-line results
March 5 2017
Webcast Event: Q1 2017 Financial Results
March 5 2017
Q1 2017 Indivior Financial Results
March 2 2017
Indivior and Virginia Commonwealth University School of Pharmacy Enter Academic Partnership
February 22 2017
Indivior PLC FY 2016 Financial Results
February 3 2017
Chief Financial Officer Announcement
February 3 2017
Indivior PLC – Appointment of Non-Executive Director
January 11 2017
Shaun Thaxter, CEO of Indivior PLC presented at the JP Morgan Healthcare Conference in San Francisco on January 11, 2017
December 12 2016
Indivior R&D Day
December 9 2016
Indivior PLC Research & Development Day in New York
November 17 2016
Indivior Applauds United States Surgeon General Report
October 3 2016
Indivior PLC (the “Company”) – Directorate Change
September 27 2016
Statement Regarding Civil Complaint Filed By State Attorneys General
September 23 2016
Indivior Notified of Civil Complaint Filed by State Attorneys General
September 20 2016
INDIVIOR GRANTS $1.2M TO THE MOYER FOUNDATION
September 12 2016
Morgan Stanley Conference, New York 2016 Presentation PDF being used at Morgan Stanley conference on 9/12/2016
August 17 2016
RBP-6000 Phase 3 Top Line Results
July 29 2016
Indivior Half Year 2016 Results
July 29 2016
H1 2016 Indivior Financial Results
July 15 2016
Indivior Announces Intention to List ADRs in U.S.
July 13 2016
Indivior Applauds Congressional Passage of Bipartisan Comprehensive Addiction & Recovery Act of 2016 (CARA)
June 7 2016
Shaun Thaxter, CEO, presented at the Jefferies Healthcare Conference in New York on Tuesday, June 7th, 2016
May 11 2016
Indivior Annual General Meeting
May 11 2016
Notice of Annual General Meeting
April 7 2016
Indivior PLC (the “Company”) – Directorate Change
February 18 2016
Webcast Event: Indivior Full Year 2015 Results – February 18, 2016
February 18 2016
Presentation: Indivior Full Year 2015 Results
February 18 2016